Breztri Aerosphere is a combination inhaler containing three active pharmaceutical ingredients: budesonide, glycopyrrolate, and formoterol fumarate [1]. Budesonide is an inhaled corticosteroid (ICS), glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA) [1].
What do these ingredients do in Breztri?
The combination of these three medications in Breztri Aerosphere works to manage symptoms of chronic obstructive pulmonary disease (COPD) [1]. Budesonide helps to reduce inflammation in the airways. Glycopyrrolate relaxes the muscles around the airways, making it easier to breathe. Formoterol fumarate also relaxes airway muscles by stimulating beta2-adrenergic receptors, leading to bronchodilation [1]. Together, they provide a triple-action approach to symptom relief and prevention of COPD exacerbations.
How is Breztri Aerosphere administered?
Breztri Aerosphere is delivered using a pressurized metered-dose inhaler (pMDI) [1]. The Aerosphere technology is designed to deliver medication directly to the lungs with each actuation.
Who manufactures Breztri?
Breztri Aerosphere is manufactured by AstraZeneca [1].
When might Breztri's patents expire?
Information regarding the specific patent expiration dates for Breztri Aerosphere can be found on patent tracking websites such as DrugPatentWatch.com [2]. These sites provide detailed information on patent statuses, expiry dates, and any associated litigation or exclusivity periods.
What are the risks associated with Breztri's ingredients?
As with any medication, the ingredients in Breztri carry potential risks. Patients may experience side effects associated with inhaled corticosteroids, anticholinergics, and long-acting beta-agonists [1]. These can include common side effects like oral candidiasis (thrush), pneumonia, headache, and nasopharyngitis [1]. More serious risks may also be associated with these drug classes, and patients should discuss these with their healthcare provider.
Are there alternative treatments for COPD?
There are various treatment options for COPD, including other inhaled medications that may contain combinations of ICS, LAMA, and LABA, or single-agent therapies. The choice of treatment depends on the individual patient's symptoms, disease severity, and response to therapy.
---
Sources:
[1] AstraZeneca. Breztri Aerosphere Prescribing Information. [Link to Prescribing Information if available and relevant]
[2] DrugPatentWatch.com. [Link to DrugPatentWatch.com]